Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
about
The detection, treatment, and biology of epithelial ovarian cancerCharacterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defenseMembrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cellsMesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerMucins in cancer: function, prognosis and therapyCirculating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancerBeyond CA125: the coming of age of ovarian cancer biomarkersMesothelin expression in the leptomeninges and meningiomasMesothelin targeted cancer immunotherapyHigh mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaA binding domain on mesothelin for CA125/MUC16Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumorsCharacterization of human mesothelin transcripts in ovarian and pancreatic cancerAdhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic optionsClinical impacts of mesothelin expression in gastrointestinal carcinomasMesothelin-Targeted CARs: Driving T Cells to Solid TumorsThe Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal MetastasisMolecular and clinical implementations of ovarian cancer mouse avatar modelsCell-cell and cell-matrix dynamics in intraperitoneal cancer metastasisDeciphering the molecular nature of ovarian cancer biomarker CA125Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinRecognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTSRole of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cellsA multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomasLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesMannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibodyNew high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaMUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouseStrategies to prevent peritoneal carcinomatosis arising from colorectal cancer.A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation.Effects of blood collection conditions on ovarian cancer serum markers.Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats.CA125/MUC16 is dispensable for mouse development and reproductionThe role of proteomics in the diagnosis and treatment of ovarian cancer.Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyMucins in ovarian cancer diagnosis and therapyRe-adapting T cells for cancer therapy: from mouse models to clinical trials.Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.The biology of ovarian cancer: new opportunities for translation
P2860
Q21198791-10F47E73-FC3B-49F7-8C3E-AC2DB522AF9CQ24336097-50F1D8DA-0739-4E66-89AD-3257FED38F18Q24601584-DF96447D-BD43-48D0-9A58-D887B4DC8E70Q24622837-5125CEE5-A61A-4A5B-BC5B-801D9A0DC9D0Q24633765-1CB1F3C4-AA71-4950-AEA5-CBB6D30EC45EQ24651062-DB1C850F-62CE-42EC-B321-4CB0E432C3FAQ24651567-D6DE91D9-6742-4670-AA71-543F61EF9823Q24654033-C9A114C0-CBA6-44EC-A035-A5C7C22C3A23Q24656242-8FFBD265-D287-4C8E-96E3-F53771B6365CQ24658024-400851BA-B929-4D45-A1AC-FA899FF6A5EFQ24658397-60CDDE72-4C9E-4AA5-B60C-022D0E355C42Q24673454-B93AFBF1-662D-42A1-80FA-5B3A18C640C9Q24791193-3F7AD292-0FD7-4D6F-9E65-FC087EC09BA7Q26748666-4FE2263A-C617-48CF-A898-3C189352C6B3Q26748680-38499EE3-FE40-4B0C-AF23-D91494E90FC2Q26778759-9A8EE4AB-82B5-4FCB-BFF4-969BE1C5506FQ26783022-2215B99D-EDA3-458B-B674-364AEF48C31CQ26786724-48417B4A-C4DE-41D1-B8F8-B13ABD942F46Q26851836-1ACF0F67-0DDF-48B8-B50A-D2946FB1011BQ27015008-736DECF6-0B92-4B14-A9C8-6A6F0F238E66Q27015134-3DCF5A4C-43BA-4C32-AB1B-E9C705D7FD46Q27670713-C0A8B134-DF9C-4323-BFFE-C7CED788EAB8Q27908595-E2F33602-A414-4AF3-B6BD-70C3BC69FAA7Q28392105-AB82CA12-D861-457D-9692-AB0DB6E6BEE5Q28395597-0E233E8A-8175-4A6E-B02C-CB9369DB0A7FQ28478285-9B7D1DC8-4075-49F7-91C6-E43058D91934Q28547381-F3961BBE-A823-423B-9D2C-8E32AB602F6DQ28594087-2B84C393-A225-4CA4-BF16-DE29D4EC3E6EQ30239825-1FE43F24-5F62-487E-93F5-42F10E0415A4Q30478956-B6E0A8C4-BCD4-4416-A0F1-1545CB303A76Q30651522-60624F5F-69EF-48A8-826A-3E7AADCAE16DQ33308744-F344459A-E35A-497A-BEEF-14A53E3BE624Q33398152-0F451D26-1E8B-4D87-A976-B827E29BD8A8Q33415034-D2054E2D-D1D2-4A13-9C79-3D5045B515D3Q33508672-9F7527AD-3948-4094-928B-9CC54B844E4EQ33574039-1AEA98D6-4B1F-4193-8304-2709783A22E4Q33583166-5464D8CF-9EE4-45EA-BBE8-6AB83C3A8745Q33588711-B5D43A56-0905-466A-BE28-A0B9BF5B90FDQ33607505-37211994-5654-4769-A5D5-134783C3FC8FQ33622369-9E2D3219-6774-45EE-9CD7-133FEE95BE14
P2860
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@ast
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en-gb
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@nl
type
label
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@ast
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en-gb
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@nl
prefLabel
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@ast
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en-gb
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@nl
P2093
P921
P3181
P356
P1476
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
@en
P2093
Armin Rump
Atsushi Miyajima
Masaki Takeuchi
Minoru Tanaka
Naohiko Umesaki
Sawako Minami
Yoshihiro Morikawa
P304
P3181
P356
10.1074/JBC.M312372200
P407
P577
2004-03-05T00:00:00Z